ara-290
ARA-290 (cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor. It promotes tissue repair and has neuroprotective properties without the blood-building effects of EPO.
Lab Notes — Research Studies
01 Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy
Investigated safety and effectiveness of ARA 290 in reducing small fiber neuropathy symptoms in 22 sarcoidosis patients, showing significant symptom improvement.
View Study ((Leiden University Medical Center))02 ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
Found ARA 290 improved blood sugar levels, lipid profiles, and reduced neuropathic pain in type 2 diabetes patients.
View Study ((Araim Pharmaceuticals))03 Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice
Demonstrated ARA290 reduces depression-like behavior in stressed mice similar to fluoxetine via anti-inflammatory effects.
View Study ((Beijing Institute of Basic Medical Sciences))04 The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain
Reviews ARA 290 as promising treatment for sarcoidosis-induced debilitating neuropathic pain.
View Study ((Leiden University Medical Center))05 ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain
Explored ARA290 effects on neuropathic pain in rats, finding dose-dependent pain reduction by decreasing inflammatory cell activity.
View Study ((Leiden University Medical Center))06 ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury
Found ARA290 improved kidney function and reduced tissue damage in pigs after induced kidney injury.
View Study ((University of Groningen))Formula — Benefits & Dosage
⚗️ Effects
- Clinical Evidence: Strong clinical trial data for neuropathy conditions.
- Targeted Action: Works specifically on tissue repair pathways.
💉 Dosage & Administration
- Clinical Dosing: 4mg subcutaneous injection, typically 3 times per week.
- Research Use: Dosing may vary in research contexts.
⚠️ Side Effects
- Generally Well Tolerated: Few adverse effects reported in clinical trials.
- Injection Site Reactions: Minor irritation at injection site possible.
📦 Availability & Sourcing
- Research Chemical: Primarily available through research chemical suppliers.
- Clinical Trials: Has been used in formal clinical trials.
- Specialized Sourcing: Not as widely available as other peptides.
Reaction Log — User Experiences
Limited user reports, but those with neuropathy report significant symptom improvement. More commonly used in clinical settings than by individual biohackers.
Synthesis — Related Compounds
⚠️ IMPORTANT DISCLAIMER
This information is for educational and research purposes only. ara-290 may not be approved for human use. Always consult a qualified healthcare professional before using any supplements or research compounds. We do not guarantee accuracy or completeness of information presented.